High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines
CONCLUSIONS: Ascorbate has potent antitumor activity and acts synergistically with carboplatin through its pro-oxidant effects. Clinical trials of ascorbate combined with carboplatin as adjuvant treatment of uterine serous carcinoma are worth exploring.PMID:38555710 | DOI:10.1016/j.ygyno.2024.03.021 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Xiaochang Shen Jiandong Wang Boer Deng Shuning Chen Catherine John Ziyi Zhao Nikita Sinha Jennifer Haag Wenchuan Sun Weimin Kong Ivan Spasojevic Ines Batinic-Haberle Angeles Alvarez Secord Chunxiao Zhou Victoria L Bae-Jump Source Type: research
TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma
CONCLUSIONS: TP53 hotspot mutations or high pathogenicity scores were not associated with platinum resistance or refractory disease. Contrary to prior studies, TP53 gain-of-function mutations were not associated with platinum resistance. Estimation of TP53 gain-of-function effect using missense mutation phenotype scores was not associated with platinum resistance. The polymorphic nature of TP53 mutations may be too complex to demonstrate effect using simple models, or response to platinum therapy may be independent of initiating TP53 mutation.PMID:38555766 | DOI:10.1016/j.ygyno.2024.03.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Lauren Montemorano Zoey B Shultz Alma Farooque Meredith Hyun Richard J Chappell Ellen M Hartenbach Jessica D Lang Source Type: research
Delayed publication of clinical trials in gynecologic oncology
CONCLUSIONS: Timely publication of clinical trials addressing gynecologic cancers remains an issue. Studies with positive findings were published faster than those with negative results, but the average publication time was still almost 2 years from trial completion. Further efforts should be made to identify and address barriers to clinical trial publication.PMID:38555709 | DOI:10.1016/j.ygyno.2024.03.018 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Julia R Salinaro Emma C Rossi Katherine N Penvose Yingao Zhang Alice J Darling Source Type: research
High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines
CONCLUSIONS: Ascorbate has potent antitumor activity and acts synergistically with carboplatin through its pro-oxidant effects. Clinical trials of ascorbate combined with carboplatin as adjuvant treatment of uterine serous carcinoma are worth exploring.PMID:38555710 | DOI:10.1016/j.ygyno.2024.03.021 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Xiaochang Shen Jiandong Wang Boer Deng Shuning Chen Catherine John Ziyi Zhao Nikita Sinha Jennifer Haag Wenchuan Sun Weimin Kong Ivan Spasojevic Ines Batinic-Haberle Angeles Alvarez Secord Chunxiao Zhou Victoria L Bae-Jump Source Type: research
TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma
CONCLUSIONS: TP53 hotspot mutations or high pathogenicity scores were not associated with platinum resistance or refractory disease. Contrary to prior studies, TP53 gain-of-function mutations were not associated with platinum resistance. Estimation of TP53 gain-of-function effect using missense mutation phenotype scores was not associated with platinum resistance. The polymorphic nature of TP53 mutations may be too complex to demonstrate effect using simple models, or response to platinum therapy may be independent of initiating TP53 mutation.PMID:38555766 | DOI:10.1016/j.ygyno.2024.03.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Lauren Montemorano Zoey B Shultz Alma Farooque Meredith Hyun Richard J Chappell Ellen M Hartenbach Jessica D Lang Source Type: research
Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer
CONCLUSIONS: Despite the higher cost, adding dostarlimab to platinum chemotherapy significantly improves QALYs, rendering this regimen cost-effective relative to chemotherapy alone for treating primary advanced or recurrent EC. Combination therapy is a cost-effective approach for this patient population compared to chemotherapy alone.PMID:38554477 | DOI:10.1016/j.ygyno.2024.03.020 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 30, 2024 Category: Cancer & Oncology Authors: Courtney J Riedinger David A Barrington Christa I Nagel Wafa K Khadraoui Paulina J Haight Crystal Tubbs Floor J Backes David E Cohn David M O'Malley Larry J Copeland Laura M Chambers Source Type: research
System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review
We present recommendations for institution-level changes which are grounded in the framework presented by the National Plan for Health Workforce Well-Being by the National Academy of Medicine. These are aimed at facilitating gynecologic oncologists' well-being and reduction of burnout. Recommendations include efforts to create a more positive and inclusive work environment, decrease administrative barriers, promote mental health, optimize electronic medical record use, and support a diverse workforce. Implementation and regular evaluation of these interventions, with specific attention to at-risk groups, is an important ne...
Source: Gynecologic Oncology - March 30, 2024 Category: Cancer & Oncology Authors: M Y Williams-Brown R M Summey A Newtson W Burke T Turner P Sabu B A Davidson G Glaser Source Type: research
Healthcare utilization in women diagnosed with endometrial cancer: A survey-based study
CONCLUSIONS: Social needs and barriers to care are most pronounced among endometrial cancer survivors earning <$25,000. Unexpectedly, and possibly related to sample size or survey tool, race/ethnicity were not zassociated with barriers to care. Further studies on health-related social needs, optimal screening tools, and effective interventions are needed in order to achieve equity in cancer outcomes for endometrial cancer patients.PMID:38554624 | DOI:10.1016/j.ygyno.2024.03.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 30, 2024 Category: Cancer & Oncology Authors: Nerlyne Desravines Dana Hazimeh Michael R Desjardins Stephanie L Wethington Source Type: research
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study
CONCLUSIONS: Detailed histologic assessment of ICS specimens appear to identify characteristics, such as inflammation and residual tumor, that may provide insight to certain clinical outcomes. Future work potentially leveraging emerging tools may provide further insight into outcomes.PMID:38554625 | DOI:10.1016/j.ygyno.2024.03.022 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 30, 2024 Category: Cancer & Oncology Authors: Paulette Mhawech-Fauceglia Denis McCarthy Akiko Tonooka Giovanni Scambia Yolanda Garcia Pavel Dundr Anne M Mills Kathleen Moore Sakiko Sanada Leslie Bradford Giulia Carlo Stella Michael Bookman Sudarshan K Sharma Frederic Selle Luciana Molinero Yvette He Source Type: research
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning
CONCLUSIONS: The MCI outperformed the conventional CCI in predicting 1-year mortality, and reducing confounding due to differences in baseline health status in comparative effectiveness analysis of NACT versus primary surgery.PMID:38554626 | DOI:10.1016/j.ygyno.2024.03.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 30, 2024 Category: Cancer & Oncology Authors: Yongmei Huang J Alejandro Rauh-Hain Thomas H McCoy June Y Hou Grace Hillyer Jennifer S Ferris Dawn Hershman Jason D Wright Alexander Melamed Source Type: research
Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033)
CONCLUSIONS: Although OP alone achieved more short-term pCR than the other groups, more recurrences occurred after pCR than LNG-IUD alone. High-dose OP as well as combination of OP and LNG-IUD did not increase pCR or reduce recurrence. Maintenance therapy may reduce the recurrence rate after pCR.PMID:38520881 | DOI:10.1016/j.ygyno.2024.03.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 23, 2024 Category: Cancer & Oncology Authors: Nam Kyeong Kim Chel Hun Choi Seok Ju Seong Jong-Min Lee Banghyun Lee Kidong Kim Source Type: research
Sentinel lymph node biopsy in high-risk endometrial cancer: The d énouement
Gynecol Oncol. 2024 Mar;182:A1-A2. doi: 10.1016/j.ygyno.2024.03.012.NO ABSTRACTPMID:38521580 | DOI:10.1016/j.ygyno.2024.03.012 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 23, 2024 Category: Cancer & Oncology Authors: Gretchen E Glaser Sean C Dowdy Source Type: research
Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033)
CONCLUSIONS: Although OP alone achieved more short-term pCR than the other groups, more recurrences occurred after pCR than LNG-IUD alone. High-dose OP as well as combination of OP and LNG-IUD did not increase pCR or reduce recurrence. Maintenance therapy may reduce the recurrence rate after pCR.PMID:38520881 | DOI:10.1016/j.ygyno.2024.03.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 23, 2024 Category: Cancer & Oncology Authors: Nam Kyeong Kim Chel Hun Choi Seok Ju Seong Jong-Min Lee Banghyun Lee Kidong Kim Source Type: research
Sentinel lymph node biopsy in high-risk endometrial cancer: The d énouement
Gynecol Oncol. 2024 Mar;182:A1-A2. doi: 10.1016/j.ygyno.2024.03.012.NO ABSTRACTPMID:38521580 | DOI:10.1016/j.ygyno.2024.03.012 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 23, 2024 Category: Cancer & Oncology Authors: Gretchen E Glaser Sean C Dowdy Source Type: research
Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033)
CONCLUSIONS: Although OP alone achieved more short-term pCR than the other groups, more recurrences occurred after pCR than LNG-IUD alone. High-dose OP as well as combination of OP and LNG-IUD did not increase pCR or reduce recurrence. Maintenance therapy may reduce the recurrence rate after pCR.PMID:38520881 | DOI:10.1016/j.ygyno.2024.03.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 23, 2024 Category: Cancer & Oncology Authors: Nam Kyeong Kim Chel Hun Choi Seok Ju Seong Jong-Min Lee Banghyun Lee Kidong Kim Source Type: research
